Nisa Investment Advisors LLC Boosts Stock Holdings in Haemonetics Co. (NYSE:HAE)

Nisa Investment Advisors LLC lifted its position in shares of Haemonetics Co. (NYSE:HAE) by 124.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,141 shares of the medical instruments supplier’s stock after acquiring an additional 632 shares during the period. Nisa Investment Advisors LLC’s holdings in Haemonetics were worth $92,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in HAE. Capital Research Global Investors boosted its stake in Haemonetics by 2.3% during the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after purchasing an additional 151,183 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Haemonetics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after purchasing an additional 57,665 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Haemonetics by 6,573.6% during the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after purchasing an additional 836,623 shares in the last quarter. Boston Trust Walden Corp boosted its position in shares of Haemonetics by 13.8% during the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock valued at $65,076,000 after buying an additional 98,019 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Haemonetics by 75.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after buying an additional 343,214 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HAE. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. CL King initiated coverage on shares of Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 target price on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research report on Monday, September 23rd. BTIG Research started coverage on Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Finally, Bank of America assumed coverage on Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $106.14.

Haemonetics Trading Up 10.7 %

Shares of HAE stock opened at $86.53 on Friday. The company has a market cap of $4.43 billion, a price-to-earnings ratio of 38.79, a PEG ratio of 1.15 and a beta of 0.32. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. The firm has a fifty day moving average price of $75.42 and a 200-day moving average price of $82.60. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. During the same quarter in the previous year, the company earned $1.05 EPS. The business’s quarterly revenue was up 8.0% compared to the same quarter last year. As a group, equities analysts predict that Haemonetics Co. will post 4.57 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.